| Savella (milnacipran) / AbbVie, Pierre Fabre |
NCT00098124: Study of Milnacipran for the Treatment of Fibromyalgia |
|
|
| Completed | 3 | 1200 | US | milnacipran hydrochloride | Forest Laboratories | Fibromyalgia | | 12/06 | | |
NCT00225511: Study Evaluating Effexor XR for Major Depression. |
|
|
| Completed | 3 | 590 | Japan | Effexor XR, Milnacipran | Wyeth is now a wholly owned subsidiary of Pfizer | Depression | | | | |
NCT00436033: A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome |
|
|
| Completed | 3 | 1429 | Europe | milnacipran, Placebo | Pierre Fabre Medicament | Fibromyalgia Syndrome | 09/07 | 09/07 | | |
NCT00314249: Study of Milnacipran for the Treatment of Fibromyalgia |
|
|
| Completed | 3 | 1025 | US | Placebo, Milnacipran 100mg | Forest Laboratories, Cypress Bioscience, Inc. | Fibromyalgia | 06/08 | | | |
NCT00618956: A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring |
|
|
| Completed | 3 | 321 | US | Milnacipran hydrochloride, Ixel (outside of United States), Placebo | Forest Laboratories, Cypress Bioscience, Inc. | Fibromyalgia | 07/08 | | | |
| Completed | 3 | 490 | Europe | milnacipran, Placebo | Pierre Fabre Medicament | Fibromyalgia Syndrome | 10/08 | 10/08 | | |
NCT00793520: Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia |
|
|
| Terminated | 3 | 2 | US | Milnacipran, Placebo | Forest Laboratories | Fibromyalgia | 04/09 | | | |
NCT00797797: Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia |
|
|
| Completed | 3 | 364 | US | No Treatment Added, Lyrica (r), Milnacipran Added | Forest Laboratories | Fibromyalgia | 11/09 | 01/10 | | |
|
NCT01221740: Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran |
|
|
| Withdrawn | 3 | 0 | US | Savella, HCL (Savella), Milnacipran | Brigham and Women's Hospital, Forest Laboratories | Back Pain | 08/11 | 08/11 | | |
NCT01418651: Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population |
|
|
| Terminated | 3 | 20 | US | Savella | Banner Health, Forest Laboratories | Fibromyalgia | 08/11 | 08/11 | | |
NCT01304589: Savella in Treatment for Provoked Vestibulodynia |
|
|
| Completed | 3 | 31 | US | Milnacipran, Savella | University of Tennessee, Forest Laboratories | Vestibulodynia, Vulvodynia | 09/12 | 09/12 | | |
NCT01829243: Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial |
|
|
| Completed | 3 | 26 | US | Milnacipran, Savella, Placebo | Duke University, Forest Laboratories | Fibromyalgia, Neurocognition | 05/13 | 05/13 | | |
NCT01288937: A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain |
|
|
| Terminated | 3 | 6 | US | Milnacipran, Savella, Placebo, Placebo Pill | Columbia University, Forest Laboratories | Idiopathic Peripheral Neuropathy | 10/14 | 12/14 | | |
2005-003137-40: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome. |
|
|
| | 3 | 160 | Europe | Milnacipran hydrochloride 25 mg, Milnacipran hydrochloride 50 mg, F02207, N06AX17 - Milnacipran, N06AX17- Milnacipran, N06AX17 - Milnacipran, N06AX17- Milnacipran | Pierre Fabre Medicament, PIERRE FABRE MEDICAMENT | Fibromyalgia, also known as FMS, is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population Fibromyalgia is associated with a reduced threshold for pain, generally identified by an increased sensitivity to pressure at particular points on the body, and is often accompanied by fatigue, sleep disturbance, and morning stiffness. Other common symptoms include headache, migraine, variable bowel habits, diffuse abdominal pain, and urinary frequency. | | 09/07 | | |
2006-003658-47: Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder. |
|
|
| Ongoing | 3 | 180 | Europe | Milnacipran, Venlafaxine, IXEL 25 mg, IXEL 50 mg, EFFEXOR 25 mg, EFFEXOR 50 mg, IXEL 25 mg, IXEL 50 mg, EFFEXOR 25 mg, EFFEXOR 50 mg | Pierre Fabre Médicament - IRPF | Major Depressive Disorder | | | | |
NCT01108731: The Effect of Milnacipran in Patients With Fibromyalgia |
|
|
| Completed | 2/3 | 37 | US | Milnacipran, Savella, Placebo | Beth Israel Medical Center | Fibromyalgia | 01/14 | 01/14 | | |
KETAPAL, NCT02783430: Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease |
|
|
| Completed | 2/3 | 42 | Europe | Ketamine, Milnacipran, Placebo | University Hospital, Lille | Depression | 03/24 | 03/24 | | |
